Vertex Pharmaceuticals Inc. is likely to have a big enough pot of cash to launch telaprevir for hepatitis C virus and to advance a potential treatment for cystic fibrosis, now that it has agreed to sell 10 million new shares. (BioWorld Today) Read More
